Go Pro

HC Wainwright Increases Earnings Estimates for Adlai Nortye

Adlai Nortye logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised Adlai Nortye’s FY2026 earnings estimate to a loss of $0.17 per share from a prior forecasted loss of $0.23, while maintaining a “Buy” rating and $20 price target.
  • Analyst sentiment is generally positive, with five Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and an average price target of $24.25.
  • Adlai Nortye shares opened at $13.34 and were up 0.7%; institutional investors own 35.21% of the company, with several firms establishing or increasing positions recently.
  • Five stocks to consider instead of Adlai Nortye.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Free Report) - Equities research analysts at HC Wainwright raised their FY2026 earnings per share estimates for Adlai Nortye in a research report issued on Friday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.17) per share for the year, up from their prior forecast of ($0.23). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Adlai Nortye's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Adlai Nortye's FY2027 earnings at ($0.16) EPS and FY2028 earnings at ($0.19) EPS.

ANL has been the topic of several other research reports. Oppenheimer initiated coverage on shares of Adlai Nortye in a research note on Thursday, May 28th. They set an "outperform" rating and a $32.00 target price on the stock. JonesTrading initiated coverage on shares of Adlai Nortye in a research note on Thursday, May 14th. They issued a "buy" rating and a $22.00 price target for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Finally, Cantor Fitzgerald began coverage on shares of Adlai Nortye in a research report on Monday, June 22nd. They set an "overweight" rating on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.

Read Our Latest Analysis on ANL

Adlai Nortye Trading Up 0.7%

NASDAQ ANL opened at $13.34 on Tuesday. Adlai Nortye has a one year low of $0.88 and a one year high of $17.25. The stock has a 50-day moving average of $11.50 and a 200 day moving average of $10.88.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. SmartHarvest Portfolios LLC boosted its position in Adlai Nortye by 8.5% in the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company's stock worth $113,000 after purchasing an additional 1,279 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Adlai Nortye during the 1st quarter valued at about $457,000. ADAR1 Capital Management LLC purchased a new stake in shares of Adlai Nortye during the 1st quarter valued at about $816,000. Affinity Asset Advisors LLC purchased a new stake in shares of Adlai Nortye during the 1st quarter valued at about $1,140,000. Finally, Boone Capital Management LLC bought a new position in shares of Adlai Nortye in the 2nd quarter worth approximately $2,971,000. Institutional investors own 35.21% of the company's stock.

About Adlai Nortye

(Get Free Report)

Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Adlai Nortye Right Now?

Before you consider Adlai Nortye, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.

While Adlai Nortye currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines